Importantly, heightened activation of the CCL1–AMFR pathway in lung tissue drives both inflammatory responses, EMT and ECM deposition, uncovering a promising therapeutic avenue against pulmonary fibrosis (31). This evidence concerns the gene AMFR and pulmonary fibrosis.